Published in Lancet on July 14, 2007
Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma | NCT00312000
International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst (2009) 2.77
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol (2011) 2.06
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer (2009) 1.75
Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. Int J Colorectal Dis (2009) 1.50
Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard? Lancet (2007) 1.45
Treatment in advanced colorectal cancer: what, when and how? Br J Cancer (2009) 1.40
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res (2014) 1.33
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC Cancer (2012) 1.30
Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int (2009) 1.25
Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol (2009) 1.24
Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer (2010) 1.21
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol (2009) 1.20
Challenges in the management of older patients with colon cancer. J Natl Compr Canc Netw (2012) 1.09
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer (2008) 1.07
Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) (2012) 1.07
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer (2010) 1.05
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer (2011) 1.05
Personalized colon cancer care in 2010. Semin Oncol (2011) 1.01
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol (2009) 1.00
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. Front Oncol (2013) 0.98
The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer. Ann Coloproctol (2013) 0.95
Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer (2009) 0.94
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist (2012) 0.94
Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol (2009) 0.93
Should noncurative resection of the primary tumour be performed in patients with stage iv colorectal cancer? A systematic review and meta-analysis. Curr Oncol (2013) 0.93
Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array. Br J Cancer (2009) 0.92
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Ther Adv Med Oncol (2011) 0.92
Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer (2012) 0.92
Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer (2014) 0.92
Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Therap Adv Gastroenterol (2008) 0.92
Genotyping of DNA samples isolated from formalin-fixed paraffin-embedded tissues using preamplification. J Mol Diagn (2010) 0.92
Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis (2015) 0.92
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs (2011) 0.91
A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. Br J Cancer (2009) 0.91
First-line chemotherapy for mCRC—a review and evidence-based algorithm. Nat Rev Clin Oncol (2015) 0.90
High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer. PLoS One (2015) 0.90
Genomic landscape of metastatic colorectal cancer. Nat Commun (2014) 0.89
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. PLoS One (2012) 0.89
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol (2009) 0.89
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer (2011) 0.88
Chromosomal copy number aberrations in colorectal metastases resemble their primary counterparts and differences are typically non-recurrent. PLoS One (2014) 0.88
Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol (2010) 0.87
Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer (2011) 0.85
Current status of pharmacological treatment of colorectal cancer. World J Gastrointest Oncol (2014) 0.85
Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. Br J Cancer (2008) 0.85
Improvements in population-based survival of patients presenting with metastatic rectal cancer in the south of the Netherlands, 1992-2008. Clin Exp Metastasis (2011) 0.84
Evolution of nonsurgical therapy for colorectal cancer. Nat Clin Pract Gastroenterol Hepatol (2009) 0.84
Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis. Cancer Metastasis Rev (2015) 0.84
GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. Br J Cancer (2008) 0.83
Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study. BMC Cancer (2016) 0.83
Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg (2013) 0.83
MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget (2015) 0.83
Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist. World J Gastroenterol (2014) 0.83
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. BMC Cancer (2014) 0.82
Strategies of sequential therapies in unresectable metastatic colorectal cancer: a meta-analysis. Curr Oncol (2014) 0.81
Survival, surgical management and perioperative mortality of colorectal cancer in the 21-year experience of a specialised registry. Int J Colorectal Dis (2009) 0.81
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterol (2015) 0.81
Capecitabine in the management of colorectal cancer. Cancer Manag Res (2011) 0.81
Treatment of colorectal cancer in the elderly. World J Gastrointest Oncol (2015) 0.81
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer (2013) 0.80
Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. Onco Targets Ther (2009) 0.79
Reduced rate of copy number aberrations in mucinous colorectal carcinoma. Oncotarget (2015) 0.79
Capecitabine for locally advanced and metastatic colorectal cancer: A review. World J Gastrointest Oncol (2010) 0.79
ABC-Transporter Expression Does Not Correlate with Response to Irinotecan in Patients with Metastatic Colorectal Cancer. J Cancer (2015) 0.78
The efficacy and safety of adding bevacizumab to cetuximab- or panitumumab-based therapy in the treatment of patients with metastatic colorectal cancer (mCRC): a meta-analysis from randomized control trials. Int J Clin Exp Med (2015) 0.78
Which strategy after first-line therapy in advanced colorectal cancer? World J Gastroenterol (2014) 0.78
How to select the optimal treatment for first line metastatic colorectal cancer. World J Gastroenterol (2014) 0.78
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: survival outcomes and patient selection. J Gastrointest Oncol (2016) 0.78
From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol (2016) 0.78
Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis (2017) 0.77
HER-2 and HER-3 expression in liver metastases of patients with colorectal cancer. Oncotarget (2015) 0.77
Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. Invest New Drugs (2010) 0.77
Colorectal hepatic metastasis: Evolving therapies. World J Hepatol (2014) 0.77
Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma. Cancer Epidemiol Biomarkers Prev (2015) 0.77
Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther (2013) 0.77
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. Springerplus (2015) 0.77
Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer. Indian J Surg Oncol (2016) 0.77
EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer. PLoS One (2015) 0.76
Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol (2014) 0.76
SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol (2015) 0.76
Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo. Cancer Med (2015) 0.76
Mitochondrial microsatellite instability in patients with metastatic colorectal cancer. Virchows Arch (2015) 0.76
Accomplishments in 2007 in the treatment of advanced colorectal cancer. Gastrointest Cancer Res (2008) 0.76
Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice. BMC Cancer (2016) 0.75
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer. Ann Gastroenterol (2012) 0.75
Efficacy of FOLFOXIRI versus XELOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer. Int J Clin Exp Med (2015) 0.75
Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'. Br J Cancer (2010) 0.75
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. J Exp Clin Cancer Res (2016) 0.75
A Successfully Resected Case of Recurrent Lung and Liver Metastases of Rectal Cancer Treated with XELIRI + Bevacizumab Therapy. Case Rep Oncol (2013) 0.75
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer. Nat Rev Clin Oncol (2009) 0.75
Developments in treating metastatic colorectal cancer: Recent international reports from ASCO 2007 and 2008. Clin Exp Gastroenterol (2009) 0.75
Profile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancer. Onco Targets Ther (2015) 0.75
Liver-directed conversion therapy in metastatic colon cancer. J Gastrointest Oncol (2015) 0.75
Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol (2016) 0.75
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med (2009) 11.63
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol (2010) 5.62
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36
BRAF mutation in metastatic colorectal cancer. N Engl J Med (2009) 3.68
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86
Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer (2007) 2.63
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res (2011) 2.52
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 2.32
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Histopathological evaluation of resected colorectal cancer liver metastases: what should be done? Histopathology (2013) 2.17
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol (2011) 2.06
Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. Radiology (2005) 2.02
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer (2010) 1.83
Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-alpha production. Blood (2008) 1.79
Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer (2011) 1.78
Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer (2012) 1.73
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res (2010) 1.69
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue. J Cell Mol Med (2010) 1.68
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther (2010) 1.67
Exercise testing and training in a cancer rehabilitation program: the advantage of the steep ramp test. Arch Phys Med Rehabil (2007) 1.62
Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol (2009) 1.60
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res (2003) 1.57
Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol (2005) 1.48
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res (2010) 1.45
Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites. Leuk Lymphoma (2013) 1.43
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol (2005) 1.36
MicroRNAs in colorectal cancer metastasis. J Pathol (2011) 1.36
Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res (2013) 1.35
PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother (2012) 1.32
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study. J Clin Oncol (2011) 1.30
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 1.29
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer (2013) 1.26
Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res (2009) 1.24
New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System. Eur J Cancer (2009) 1.23
Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol (2013) 1.23
Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ (2006) 1.22
Hypoxia in relation to vasculature and proliferation in liver metastases in patients with colorectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.20
Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci U S A (2011) 1.19
Long-term cancer survivors experience work changes after diagnosis: results of a population-based study. Psychooncology (2009) 1.17
Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. Eur J Cancer (2010) 1.17
Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study. Cancer (2007) 1.16
Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother (2008) 1.15
Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer (2006) 1.14
Phenotypical and functional characterization of clinical grade dendritic cells. J Immunother (2002) 1.12
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer (2005) 1.12
Development of generic quality indicators for patient-centered cancer care by using a RAND modified Delphi method. Cancer Nurs (2011) 1.11
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J Natl Cancer Inst (2009) 1.11
Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res (2012) 1.11
Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol (2005) 1.11
Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther (2008) 1.11
Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer (2014) 1.11
Novel insights into pathological changes in muscular arteries of radiotherapy patients. Radiother Oncol (2009) 1.08
Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood (2010) 1.07
Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. PLoS One (2013) 1.04
Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used. Cancer Immunol Immunother (2010) 1.04
Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. Eur J Cancer (2011) 1.04
Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med (2006) 1.03
Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res (2012) 1.03
Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res (2010) 1.03
In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res (2009) 1.02
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam. Invest New Drugs (2005) 1.01
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041). Clin Cancer Res (2010) 1.00
Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat (2008) 1.00
Rehabilitation using high-intensity physical training and long-term return-to-work in cancer survivors. J Occup Rehabil (2012) 1.00
Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast (2007) 0.99
Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use? Crit Rev Oncol Hematol (2012) 0.99
Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer (2008) 0.99
Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters. Int J Radiat Oncol Biol Phys (2004) 0.96
Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res (2010) 0.96
Löffler endocarditis: a rare cause of acute cardiac failure. J Cardiothorac Surg (2012) 0.95
Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg (2014) 0.95
Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer (2004) 0.94
Can an online clinical data management service help in improving data collection and data quality in a developing country setting? Trials (2011) 0.94
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours. Eur J Cancer (2010) 0.93
Very late relapse in diffuse large B-cell lymphoma represents clonally related disease and is marked by germinal center cell features. Blood (2003) 0.93
Effect of the new HJV-L165X mutation on penetrance of HFE. Blood (2007) 0.93